Company intelligence / Profile preview

TiGenix

Ownership: Private
Employees: ~80
Development stage: Commercial

Overview

TiGenix successfully completed a European Phase III clinical trial for Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients. The CHMP of the EMA adopted a positive opinion recommending marketing authorization for Cx601, making it the first allogeneic stem cell therapy to achieve this milestone. Results were published in The Lancet in July 2016.

Therapeutic areas: GastroenterologyCardiovascularRheumatologyImmunologyInfectious Diseases
Modalities: Cell therapyStem cell therapyAllogeneic expanded adipose-derived stem cells (eASC)Cardiac stem cells
Industry: Biotech

Drug pipeline

3 assets

darvadstrocel

Commercial

Indications: Complex perianal fistulas in Crohn's disease

2 more assets in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company Limited

Beyond the preview

Go deeper on TiGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TiGenix.

Explore the full profile